Stage, age, and EBV status impact outcomes of plasmablastic lymphoma patients: a clinicopathologic analysis of 61 patients

Sanam Loghavi(The University of Texas MD Anderson Cancer Center), Joseph D. Khoury(St. Jude Children's Research Hospital), Shimin Hu(The University of Texas MD Anderson Cancer Center), Guilin Tang(The University of Texas MD Anderson Cancer Center), Roberto N. Miranda, Tariq N. Aladily(University of Jordan), Siok‐Bian Ng(National University of Singapore), Zhuang Zuo(The University of Texas MD Anderson Cancer Center), L. Jeffrey Medeiros(The University of Texas MD Anderson Cancer Center), Khaled Alayed(The University of Texas MD Anderson Cancer Center), C. Cameron Yin(The University of Texas MD Anderson Cancer Center)
Journal of Hematology & Oncology
June 10, 2015
10.1186/s13045-015-0163-z
Cited by 139

Related Papers

The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms
|Leukemia|2022|3.8k
Inhibition of JNK activation through NF-κB target genes
|Nature|2001|719
MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program
|Blood|2013|677
Complete Surgical Excision Is Essential for the Management of Patients With Breast Implant–Associated Anaplastic Large-Cell Lymphoma
|Journal of Clinical Oncology|2015|418
Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study
|Blood|2012|390